JSS Medical Research, the full-service contract research organisation (CRO) based in Montreal, Canada, has completed the acquisition of LatAm Clinical Trials, a multinational CRO operating in South and Central America, for an undisclosed sum.
Founded by a group of entrepreneurs in 2005, LatAm Clinical Trials provides clinical-research support to the pharmaceutical industry across Phase I to IV as well post-marketing studies, JSS Medical said.
The acquired company's service portfolio includes study start-up, regulatory support, project management, site management monitoring, quality assurance and training.
Geographically,LatAm Clinical Trials runs offices in the US, Colombia and Panama.
It also fields clinical-research staff in a number of the Andean countries of South and Central America, including Colombia, Panama, Costa Rica, Guatemala, Dominican Republic, Peru, Venezuela and Ecuador.
This offers access to “substantial under-utilised medical expertise and infrastructure” throughout the region, JSS Medical noted.
LatAm Clinical Trials' geographic reach in Latin America also extends to Mexico, Argentina, Brazil and Chile through partnerships with other local CROs.
The acquisition of LatAm Clinical Trials represents “a key milestone for JSS Medical Research in its route to becoming a leading international niche CRO”, the company stated.
JSS Medical is “constantly improving” its service offerings, both in terms of geographic reach and scope of services, by responding to industry demands and the specific needs of its clientele, commented Dr. John Sampalis, the company's founder and chief executive officer.
The addition of LatAm Clinical Trials to JSS Medical Research “solidifies our presence in Latin America, allowing us to extend our services in the region and enhancing our current position by adding regional clinical services in addition to the already established scientific, data management, biostatistical, outcomes research, health economics and medical writing services”, Sampalis noted.
LatAm Clinical Trial's emphasis on high-quality clinical operations, together with a management team comprising clinicians, epidemiologists and clinical researchers, is “entirely compatible” with the JSS Medical Research vision, he added.
Supplementing its Phase I-IV offering, these synergies will enable JSS Medical to help its industry and government partners design and execute “much needed” post-approval programmes in clinical epidemiology, Sampalis pointed out.